[go: up one dir, main page]

MX2009003679A - Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores. - Google Patents

Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores.

Info

Publication number
MX2009003679A
MX2009003679A MX2009003679A MX2009003679A MX2009003679A MX 2009003679 A MX2009003679 A MX 2009003679A MX 2009003679 A MX2009003679 A MX 2009003679A MX 2009003679 A MX2009003679 A MX 2009003679A MX 2009003679 A MX2009003679 A MX 2009003679A
Authority
MX
Mexico
Prior art keywords
tumor
composition
fragment
eliciting
encodes
Prior art date
Application number
MX2009003679A
Other languages
English (en)
Inventor
Rong Xiang
Ralph A Reisfeld
Yunping Luo
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MX2009003679A publication Critical patent/MX2009003679A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una composición de ADN, útil para provocar una respuesta inmune contra los macrófagos asociados a los tumores, comprende un constructo de ADN que codifica para una cistein endopeptidasa (por ejemplo, legumain) o un polipéptido que comprende al menos un fragmento inmunogénico de la misma la cual es sobreexpresada en las células asociadas a los tumores como los macrófagos asociados a tumores o un fragmento inmunogénico de la misma el cual es expresable en las células inmunes y que es incorporado en un portador farmacéuticamente aceptable. En las modalidades preferidas, la composición codifica un polipéptido que comprende una pluralidad de fragmentos inmunogénicos de una cistein endopeptidasa asociada a tumores (por ejemplo, legumain) unidos de manera serial tal que cada fragmento esta conectado a al menos uno de otros fragmentos por un péptido enlazador como AlaAlaAla o AlaAlaTyr. En una descripción detallada del método, la composición también incluye un constructo de ADN que codifica una proteína efectora inmune, como una citoquina. La composición de ADN de la invención puede ser utilizada sola o en combinación con un agente quimioterapéutico para tratar enfermedades como tumores y las metástasis tumorales.
MX2009003679A 2006-10-06 2007-10-05 Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores. MX2009003679A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84992706P 2006-10-06 2006-10-06
PCT/US2007/021414 WO2008054612A2 (en) 2006-10-06 2007-10-05 Dna composition for eliciting an immune response against tumor-associated macrophages

Publications (1)

Publication Number Publication Date
MX2009003679A true MX2009003679A (es) 2009-04-23

Family

ID=39344839

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003679A MX2009003679A (es) 2006-10-06 2007-10-05 Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores.

Country Status (11)

Country Link
US (2) US20090275642A1 (es)
EP (1) EP2069378B1 (es)
JP (1) JP2010514673A (es)
KR (1) KR20090092271A (es)
CN (1) CN101553498B (es)
AU (1) AU2007314433B9 (es)
CA (1) CA2664308A1 (es)
ES (1) ES2605020T3 (es)
MX (1) MX2009003679A (es)
RU (1) RU2459631C2 (es)
WO (1) WO2008054612A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2496876C1 (ru) * 2012-07-18 2013-10-27 Федеральное государственное бюджетное учреждение науки Институт цитологии и генетики Сибирского отделения Российской академии наук (ИЦиг СО РАН) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pMALTEV-legumain, КОДИРУЮЩАЯ ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ АНТИГЕННЫМИ СВОЙСТВАМИ БЕЛКА ЛЕГУМАИН Opisthorchis felineus, И ШТАММ E.coli BL 21(DE3)pLysS-pMALTEV-legumain - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АНТИГЕННЫМИ СВОЙСТВАМИ БЕЛКА ЛЕГУМАИН Opisthorchis felineus
CA2940794C (en) * 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
WO2018058002A1 (en) * 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
US20200123566A1 (en) * 2017-06-13 2020-04-23 Oncosec Medical Incorporated Multigene construct for immune-modulatory protein expression and methods of use
CN108409866A (zh) * 2018-01-23 2018-08-17 合肥瑞城生生物科技有限公司 一种用于治疗和预防人乳头瘤病毒感染及相关疾病的多表位组合肽
CN112608903A (zh) * 2020-12-24 2021-04-06 杭州中赢生物医疗科技有限公司 一种淋巴细胞及其培养体系和培养方法
CN113321721B (zh) * 2021-06-11 2022-06-03 中南大学湘雅二医院 一种细胞外Ezrin蛋白及其应用
CN113789387B (zh) * 2021-11-15 2022-02-22 中国医学科学院北京协和医院 标志物在诊断腹主动脉瘤中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8681B (en) 1985-01-07 1987-08-26 Syntex Inc 1,2-dialkoxy-omega-trialkylammonium cationic surfactants
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US5807552A (en) * 1995-08-04 1998-09-15 Board Of Regents, The University Of Texas System Compositions for conferring immunogenicity to a substance and uses thereof
US7303752B2 (en) * 2001-10-17 2007-12-04 The George Washington University Hookworm vaccine
CN101374856A (zh) * 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成

Also Published As

Publication number Publication date
AU2007314433A1 (en) 2008-05-08
ES2605020T3 (es) 2017-03-10
CA2664308A1 (en) 2008-05-08
EP2069378B1 (en) 2016-10-05
JP2010514673A (ja) 2010-05-06
CN101553498A (zh) 2009-10-07
AU2007314433B9 (en) 2014-02-20
US20090275642A1 (en) 2009-11-05
US20150175996A1 (en) 2015-06-25
AU2007314433B2 (en) 2013-09-05
WO2008054612A9 (en) 2008-07-03
WO2008054612A2 (en) 2008-05-08
KR20090092271A (ko) 2009-08-31
RU2009117246A (ru) 2010-11-20
RU2459631C2 (ru) 2012-08-27
WO2008054612A3 (en) 2008-10-09
EP2069378A2 (en) 2009-06-17
CN101553498B (zh) 2012-08-08
EP2069378A4 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
MX2009003679A (es) Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores.
WO2007149518A3 (en) Dna composition against tumor stromal antigen fap and methods of use thereof
WO2007028574A3 (en) Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
WO2008079172A3 (en) Compositions comprising hmw-maa and fragments thereof, and methods of use thereof
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
GB201004575D0 (en) Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
NO20081690L (no) Tumorassosierte peptider som bindes til humant leukocyttantigen (HLA) klasse I- eller II-molekyler og relatert vaksine mot kreft
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
MX2021011653A (es) Composiciones inmunoterapeuticas y uso de las mismas.
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
WO2011123813A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2006037421A3 (en) Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
EP1716173B8 (en) Carcinoembryonic antigen fusion protein and uses thereof
ATE485059T1 (de) Tumortherapie mit vektoren auf sindbis virus- basis
EP1934246B8 (en) Matrix metalloproteinase 11 vaccine
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide
WO2024243227A3 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use
MX2025000487A (es) Anticuerpos anti-mesotelina
WO2007059030A3 (en) Llo-encoding dna/nucleic acid vaccines and methods comprising same

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration